Werner Poewe

Werner Poewe

Auto-generated profile, based on publicly available information

Werner Poewe

Department of Neurology Medical University of Innsbruck Innsbruck Austria

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in The Lancet Neurology
Verified
Journal Article
Closed access
ETEduardo Tolosa
Eduardo Tolosa
AGAlicia Garrido
Alicia Garrido
SSSonja W Scholz
Sonja W Scholz
WPWerner Poewe
Werner Poewe

17 March 2008 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
WPW. Poewe
W. Poewe

1 June 2007 in The Lancet Neurology
Verified
Journal Article
Closed access
WPWerner H Poewe
Werner H Poewe
OROlivier Rascol
Olivier Rascol
NQNiall Quinn
Niall Quinn
ETEduardo Tolosa
Eduardo Tolosa
WOWolfgang H Oertel
Wolfgang H Oertel
BBBabak Boroojerdi
Babak Boroojerdi

25 August 2022 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
WPWerner Poewe
Werner Poewe
ISIva Stankovic
Iva Stankovic
GHGlenda Halliday
Glenda Halliday
WMWassilios Meissner
Wassilios Meissner
GWGregor K. Wenning
Gregor K. Wenning
HKHoracio Kaufmann
Horacio Kaufmann

17 October 2015 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
PDF file
PMPhilipp Mahlknecht
Philipp Mahlknecht
KSKlaus Seppi
Klaus Seppi
WPWerner Poewe
Werner Poewe
Parkinson’s disease (PD) is currently clinically defined by a set of cardinal motor features centred on the presence of bradykinesia and at least one additional motor symptom out of tremor, rigidity or postural instability. However, converging eviden

1 December 2017 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
Angelo AntoniniAngelo Antonini
Angelo Antonini
WPWerner Poewe
Werner Poewe
Kallol (K) Chaudhuri also Ray-ChaudhuriKallol (K) Chaudhuri also Ray-Chaudhuri
Kallol (K) Chaudhuri also Ray-Chaudhuri
RJRobert Jech
Robert Jech
BPBarbara Pickut
Barbara Pickut
MZMichel Van Zandijcke
Michel Van Zandijcke
This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care. Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients with ≤12 months of pre-treatment with LCIG (40% of patients). Hours of "On" and "Off" time were assessed with a modified version of the Unified Parkinson's Disease Rating Scale part IV items 32 and 39. Overall, 375 patients were enrolled by 75 movement disorder centers in 18 countries and 258 patients completed the registry. At 24 months LCIG treatment led to significant reductions from baseline in "Off" time (hours/day) (mean ± SD = -4.1 ± 3.5, P < 0.001), "On" time with dyskinesia (hours/day) (-1.1 ± 4.8, P = 0.006), Non-Motor Symptom Scale total (-16.7 ± 43.2, P < 0.001) and individual domains scores, and Parkinson's Disease Questionnaire-8 item total score (-7.1 ± 21.0, P < 0.001). Adverse events deemed to have a possible/probable causal relationship to treatment drug/device were reported in 194 (54%) patients; the most frequently reported were decreased weight (6.7%), device related infections (5.9%), device dislocations (4.8%), device issues (4.8%), and polyneuropathy (4.5%). LCIG treatment led to sustained improvements in motor fluctuations, non-motor symptoms particularly sleep/fatigue, mood/cognition and gastrointestinal domains, as well as quality of life in advanced PD patients over 24 months. Safety events were consistent with the established safety profile of LCIG.